Liquidia Jefferies London Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thanks so much for joining us at Jefferies London Healthcare Conference. My name is Albert Zhang, associate on Akash Tewari's team here at Jefferies. I work closely with Manoj, who covers Liquidia and has done some really great work here. I am pleased to welcome Michael Kaseta, Chief Operating Officer, Chief Financial Officer from Liquidia, and Jason Adair, Chief Business Officer. Before we jump into questions, I will turn it over to Michael and Jason for opening remarks.
Yeah. Thanks, Albert, for having us. Really appreciate being here at Jefferies. Just first, Roger does send his regards. He did get hung up in some of the travel disruption this weekend and was unable to make it, so Jason and I will try to hold the fort down here. First, I think what is most important for us is, patients are at the center of everything we do as a company at Liquidia. This is why the settlement that we entered into in October was so important. It gives certainty to existing PH-ILD patients, who benefit so greatly from our drug. It also gives certainty to the PAH community as a whole. For where we are right now, we couldn't be more excited for the path forward. All we have done since June of 2025, when we launched YUTREPIA, was execute.
We have been able to achieve over a 30% market share by the end of September, in an entrenched market where the market leader had a 20-year head start. We have the best sales team, the best commercial team, the best market access team, and we have a first-class patient support services program. As we move forward through the rest of 2026 and into 2027, we couldn't be more excited for what is to come. We feel extremely lucky to be able to service these patients as we move forward, especially these PAH patients, and look forward to a great year in 2027 and beyond.
Great. Thanks so much. Maybe you can start off with a bigger picture question. With litigation overhang now removed, I think investors can now shift their attention to the underlying business and the pipeline. As you look through 2027, and maybe even further out to 2028, 2029, what would you highlight as the two or three most important milestones for the Liquidia story? Perhaps more specifically, what do you think the investors are still underappreciating about Liquidia's growth opportunity here?
Yeah, it's a great question. As we look, really, the world changed the day we signed that settlement in mid-October. I think what's most important for the rest of 2026 is to show that we can still be a growth story. We feel that we're in a really good position. At earnings last week, we talked about where we were as of, for the month of October, and what I would say, and I don't think this is controversial, we believe October of 2026 is going to be the most disruptive month of our launch. If you look at our referral rate in October of 2026, it was at 75% of where we were in Q3 on a daily rate. We're very happy with that. We're very encouraged with what we've seen in October. We're very encouraged with what we've seen for the first half of November.
We believe that we're going to grow from this base as we move forward, and that is extremely important for how we see the PAH market for YUTREPIA moving into 2026, through the rest of 2026 and into 2027 and 2028. But like Roger said, we are a show-me story. We're planning to do that. We're planning to do that while also achieving over 50% operating margins in 2027. So, our SG&A expenses as a percentage of sales will come down quarter on quarter. We will grow our R&D costs quarter on quarter as we move forward. This time next year, our plan is to have 10 clinical trials in place, three of which will be registrational studies with L606 in PH-COPD, in PH-ILD, and hopefully also be in a pivotal phase III study in systemic sclerosis with Raynaud's phenomenon.
So, it is an exciting time for Liquidia, and I think for us, it's all about execution now. As you said, the legal overhang is gone. We can focus solely on the task at hand here, and we feel that it is a great time at Liquidia, and we're going to create a tremendous amount of value for shareholders, and most importantly, we're going to provide a tremendous amount of benefit for patients.
Got it. Understood. I want to first touch on YUTREPIA and its commercial opportunity. You've talked about roughly 25K treated PAH patients are now already receiving a prostacyclin, and importantly, you've positioned YUTREPIA as an option not just for patients on inhaled therapies, but also potentially for patients on oral and parenteral as well. If we think about those three existing treatment pools, oral, inhaled, and parenteral, which do you see as the most actionable switching opportunity over the next 12 or 24 months?
Yeah. What I think is most exciting about YUTREPIA is obviously our product profile and the flexibility that we provide. Our ability to titrate to higher doses, we believe, than any other inhaled prostacyclin. We're also the only inhaled prostacyclin in our label having a dosing regimen of between three and five times per day. We look at the entire opportunity. If you look at the prostacyclin market in PAH, it's roughly $4 billion in total, based on our estimates. We believe we have access to the vast majority of that $4 billion. This is why, as part of those 10 trials that I talked about, we're going to do a lot of phase IV open-label studies in oral transitions. We're going to do a study showing YUTREPIA using it only three times a day. We're going to do a study of parenteral transitions on background WINREVAIR therapy.
We're excited. We think that this opportunity in PAH is a massive opportunity for us. It is our primary focus as we move forward. As I said, we have a sales force that is laser-focused with tremendous relationships. And again, we feel very confident that we're going to be able to continue to deliver and continue to deliver sequential growth as we move forward through the rest of 2026 and through 2027.
I just want to follow up a quick one on the oral side. You have an ongoing study looking at transitions from selexipag, I believe, and how important is establishing a standardized transition protocol to unlock that population there?
Sure, I can take that. A lot of what we're doing with phase IV is to create data that will be ours that we can publish, but it's really reflecting what's already happening in the real world. So to the point that since launch, we've seen transitions, and we've seen patients go from an oral phosphodiesterase to inhaled. And one of the main reasons for that has to do with tolerability. So, we think of inhaled as local delivery for local disease. The oral products, you literally have to gut through them as they activate receptors in the intestines. So let's avoid all of that. And so, we have entered a single-site study where we're going to look to move patients from oral selexipag to doses of YUTREPIA and see if we can take them higher.
The ultimate goal is to see if we can make those patients better or get more utility out of it. But the primary goal for that study is really safety, that we are transitioning those patients in a safe way, not putting them at risk, and then see if we can make them better. Our hope is that that data then will also start to inform maybe an algorithm that we could use in our medical information to explain to other physicians how they could safely titrate patients.
Excellent. Just maybe continue on the commercial side. Another important question following the settlement is obviously, how are we thinking about existing PH-ILD patients on YUTREPIA? You have been clear that patients already receiving YUTREPIA for PH-ILD are not required to switch, and so far, you are not seeing formulary changes or indications that payers are proactively trying to move patients into alternative therapies. As we move into 2027 and annual reauthorization begins, how should we think about the actual risk to existing PH-ILD patients?
Yeah, so when we think about existing patients, one of the things we talked about at earnings last week was that we shipped to more patients in October of 2026 than in any other month during the launch. So, we have a great patient base that is growing. As you said, what happens in the reauthorization process in early 2027? The reauthorization process is very simple. It is a communication between payers and doctors, and the two main questions that are asked are, is the patient still on the therapy, and is the patient still benefiting from that therapy? Nothing that has happened in the last 60 days impacts that. We have contracted broadly across both Part D and commercial. We do not see any changes, and therefore, our belief is that if a doctor wants to keep an existing PH-ILD patient on YUTREPIA, they will be able to do that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
